Public Release: 

Late-breaking science announced for the Structural Heart Disease Summit 2018

CRF meeting covering the latest in transcatheter valve therapies and LAA and PFO closure will take place June 20-23 in Chicago

Cardiovascular Research Foundation

WHAT: The Cardiovascular Research Foundation (CRF) has announced that the Structural Heart Disease Summit 2018 will feature three studies which will be presented as Late-Breaking Science on Friday, June 22nd in the Sheraton Chicago Ballroom IV- VII from 2:45 PM - 3:30 PM. They include the following studies:

Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device: The SAFE MANTA Study David A. Wood

Early Commercial Experience Using the PORTICO Transcatheter Aortic Valve: 30-Day Outcomes in 973 Patients Enrolled in the Portico I Study (Cohort A) Francesco Maisano

Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure Patrick Klein

New this year, Transcatheter Valve Therapies (TVT) 2018, featuring practical clinical workshops, innovation sessions, and live case demonstrations, is the first part of a comprehensive congress called The Structural Heart Disease Summit. It will be followed by a live case demonstration course on LAA and PFO Closure. TVT 2018 is a practical three-day course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. For more than 10 years, TVT has provided healthcare professionals with the latest advances, tools, and techniques for the treatment of valvular heart disease using nonsurgical procedures. LAA and PFO Closure 2018 will provide cardiologists and other healthcare providers with the latest information on the technologies, indications, and outcomes of left atrial appendage (LAA) and patent foramen ovale (PFO) closure to prevent cardioembolic stroke. Live cases will be performed by experts in the field to demonstrate firsthand basic and advanced techniques of LAA and PFO closure.

The agenda for both courses are now available online:

TVT Agenda:

LAA/PFO Agenda:

The Structural Heart Disease Summit will also feature Interactive Training Workshops where clinicians and members of the Heart Team can learn new skills they can apply immediately to their practice. Workshop topics include Trans-septal Puncture, LAA and PFO Closure, Advanced TAVR Training, and Basic and Advanced Mitral Repair. Additional information can be found online at: WHY: Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can lead to heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, there have been important advances in concepts, tools, techniques, and patient selection using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.

WHEN: June 20-23, 2018

WHERE: Sheraton Grand Chicago 301 East North Water Street Chicago, IL 60611

HOW TO REGISTER: Media may apply for registration by emailing

About CRF

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease. For more information, visit


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.